Parkinson Disease Neural Circuitry and Gastrointestinal Pathobiology
帕金森病神经回路和胃肠道病理学
基本信息
- 批准号:10740119
- 负责人:
- 金额:$ 58.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAgeAgingAnimal ModelAttentionAutonomic DysfunctionAutonomic PathwaysBiochemicalBraak&aposs hypothesisBrainBrain StemCell NucleusCentral Nervous SystemCerebral cortexClinicClinicalClinical TrialsCognitiveColonConstipationControl GroupsCorpus striatum structureDeglutition DisordersDopamineDopamine ReceptorDuodenumEducational workshopElderlyEnteralEnteric Nervous SystemEnteroendocrine CellFunctional disorderFutureGastric EmptyingGastroenterologyGastrointestinal TransitGastrointestinal tract structureGut MucosaHumanImageImpaired cognitionIndividualInfectious AgentInflammationInterventionIntestinal permeabilityIntestinesInvestigationLiteratureMolecularMotorMucous MembraneNauseaNerveNerve DegenerationNervous SystemNeurodegenerative DisordersNeuronsParkinson DiseasePathologicPathway interactionsPatientsPermeabilityPersonsPharmaceutical PreparationsPhenotypePhysiologicalPoisonPreventionProcessProspective cohortProteinsQuality of lifeQuestionnairesResearch DesignRoleShort-Term MemorySigmoid colonSmall IntestinesSpecificitySqualamineStomachSubmucosaSymptomsTight JunctionsTimeTissuesTravelUnited States National Institutes of HealthVagus nerve structureabsorptionalpha synucleinbasal forebraincell motilitycognitive impairment in Parkinson&apossdensitydesigndopamine transporterdopaminergic neurondorsal motor nucleusfecal microbiomegastrointestinalgastrointestinal functiongastrointestinal symptomgut microbiotagut-brain axisimprovedin vivointestinal epitheliummicrobiomemotility disordermotor disordermotor symptommultidisciplinaryneuralneural circuitneurotoxicoccludinpreclinical studyprospectiveprotein misfoldingreceptor densityreceptor expressionsingle photon emission computed tomographysynucleinopathytranscriptome
项目摘要
Gastrointestinal (GI) symptoms are significant non-motor manifestations of Parkinson disease (PD) that can precede PD motor symptoms by years; cognitive dysfunction is an important late, non-motor manifestation. Braak’s hypothesis proposes that α-synuclein (αS) aggregates propagate along vagal or olfactory afferents to the central nervous system (CNS), leading to motor and non-motor features of PD. However, αS aggregates are also identified in enteric neurons in elderly people without PD. Squalamine prevention of αS aggregates improved constipation in PD. Density of nigrostriatal dopamine transporters (as assessed by 123I-FP-CIT SPECT) are relevant to cognitive processing in PD. αS oligomers in CSF is a marker of early synucleinopathies and αS protein misfolding in PD implies propagation from the gut to brainstem via the vagus nerve. The relationship between density of nigrostriatal dopamine or aS misfolding in gastrointestinal mucosa and the GI pathophysiology in human PD is unknown. To date, prior studies have typically addressed one pathological mechanism and one GI manifestation. Our multidisciplinary characterization of GI and neural phenotype in PD is key for this first study in 3 groups of humans of the mechanistic roles of the central neural circuitry, central dopamine receptors’ density, autonomic pathways, as well as αS expression in the gastrointestinal and colonic mucosa and microbiome in gut pathophysiology in human PD. Our overall hypothesis is that reduced nigrostriatal dopamine transmitter, autonomic dysfunction and increased αS expression or misfolding in the gastric, duodenal or sigmoid mucosa are associated with abnormal GI motor and barrier functions and with submucosal neuronal dopamine and αS expression in patients with PD with GI symptoms. We propose a prospective cohort design study with two aims in 3 groups, that is, PD patients with Hoehn and Yahr motor stages 1-3 with/without GI symptoms, and age-matched controls with n=24 per group:
Aim 1: To compare GI motor functions (gastric emptying and accommodation, colonic transit, defecatory function), small bowel permeability, duodenal and stool microbiome and putative mechanisms (GI and sigmoid mucosal transcriptome, including αS misfolding, tight junction protein, and dopamine receptor expression).
Aim 2: To quantitate nigrostriatal dopamine transporter expression, autonomic symptoms, and vagal and sympathetic functions using validated 123I-FP-CIT SPECT, COMPASS-31 questionnaires, and CASS scores, respectively and compare the central dopamine transporter expression and autonomic functions
In sub-aims, we compare central and autonomic functions, GI transit and permeability, and mucosal αS mucosal expression or mis-folding in the 3 groups. The significance of the proposal lies in identification of mechanisms, and potential targets for future interventions directed to vagal and autonomic dysfunction, aggregation or misfolding of αS in gut mucosa, as well as dopamine expression to treat GI manifestations of PD.
胃肠道(GI)症状是帕金森病(PD)的重要非运动表现,可先于PD运动症状多年;认知功能障碍是一种重要的晚期非运动表现。Braak的假说认为α-突触核蛋白(αS)聚集体沿着迷走神经或嗅觉传入神经传播到中枢神经系统(CNS),导致PD的运动和非运动特征。然而,在无PD的老年人的肠神经元中也发现了αS聚集体。角鲨胺预防αS聚集体改善PD患者便秘。黑质纹状体多巴胺转运蛋白的密度(如通过123 I-FP-CIT SPECT评估的)与PD中的认知处理相关。CSF中的αS寡聚体是早期突触核蛋白病的标志物,PD中的αS蛋白错误折叠意味着通过迷走神经从肠道传播到脑干。黑质纹状体多巴胺密度或胃肠道粘膜中的aS错误折叠与人类PD中的GI病理生理学之间的关系尚不清楚。到目前为止,先前的研究通常解决了一种病理机制和一种GI表现。我们对PD中GI和神经表型的多学科表征是在3组人类中首次研究中枢神经回路、中枢多巴胺受体密度、自主通路以及胃肠道和结肠粘膜中αS表达和微生物组在人类PD肠道病理生理学中的机制作用的关键。我们的总体假设是,黑质纹状体多巴胺递质减少、自主神经功能障碍和胃、十二指肠或乙状结肠粘膜中αS表达增加或错误折叠与GI运动和屏障功能异常以及伴有GI症状的PD患者的粘膜下神经元多巴胺和αS表达相关。我们提出了一项前瞻性队列设计研究,在3组中有两个目的,即Hoehn和Yahr运动1-3期伴/不伴GI症状的PD患者和年龄匹配的对照组,每组n=24:
目标1:比较GI运动功能(胃排空和调节、结肠运输、排便功能)、小肠通透性、十二指肠和粪便微生物组和假定机制(GI和乙状结肠粘膜转录组,包括αS错误折叠、紧密连接蛋白和多巴胺受体表达)。
目标二:分别使用经验证的123 I-FP-CIT SPECT、COMPASS-31问卷和卡斯评分定量黑质纹状体多巴胺转运蛋白表达、自主神经症状以及迷走神经和交感神经功能,并比较中枢多巴胺转运蛋白表达和自主神经功能
在子目标中,我们比较了3组中的中枢和自主神经功能、GI运输和渗透性以及粘膜αS粘膜表达或错误折叠。该提案的意义在于确定机制和未来针对迷走神经和自主神经功能障碍、肠道粘膜中αS聚集或错误折叠以及多巴胺表达的干预措施的潜在靶点,以治疗PD的GI表现。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL L. CAMILLERI其他文献
MICHAEL L. CAMILLERI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL L. CAMILLERI', 18)}}的其他基金
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
G-POEM 治疗胃轻瘫的随机对照试验,旨在评估可行性、安全性、有效性和生理机制
- 批准号:
10843438 - 财政年份:2023
- 资助金额:
$ 58.43万 - 项目类别:
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
G-POEM 治疗胃轻瘫的随机对照试验,旨在评估可行性、安全性、有效性和生理机制
- 批准号:
10416023 - 财政年份:2021
- 资助金额:
$ 58.43万 - 项目类别:
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
G-POEM 治疗胃轻瘫的随机对照试验,旨在评估可行性、安全性、有效性和生理机制
- 批准号:
10211000 - 财政年份:2021
- 资助金额:
$ 58.43万 - 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性
- 批准号:
9983012 - 财政年份:2019
- 资助金额:
$ 58.43万 - 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性
- 批准号:
10404023 - 财政年份:2019
- 资助金额:
$ 58.43万 - 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性
- 批准号:
9796963 - 财政年份:2019
- 资助金额:
$ 58.43万 - 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性
- 批准号:
10165708 - 财政年份:2019
- 资助金额:
$ 58.43万 - 项目类别:
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome
胆汁酸、遗传控制和肠易激综合症的结肠功能
- 批准号:
8536669 - 财政年份:2011
- 资助金额:
$ 58.43万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 58.43万 - 项目类别:
Research Grant